CDK4 and neoplasm: More recently, preclinical and clinical reports suggested synergism between CDK4/6 and RAF/MAPK pathway inhibitors, including modulation of the tumor and immune microenvironment, and antitumor responses were observed in pancreatic cancer patients.38, 39, 40, 41